Several lines of evidence have shown that patients with depression have higher rates of substance-use disorders than the general population1,2

The presence of a major depressive episode increases the risk of drug dependence by 4.3 times,3 however, the relationship between substance-use disorder and MDD is bidirectional4

One meta-analysis, including 48 studies and 348,550 people, found a prevalence of substance-use disorder in men with MDD of 36%, and in women of 19%5

In an analysis of the STAR*D study data, patients with MDD and comorbid substance-use disorder were more likely to:6 6

  • Have earlier onset of depression
  • Experience greater depressive symptomatology
  • Experience greater functional impairment
  • Have a greater suicide risk

MDD=major depressive disorder; STAR*D=Sequenced Treatment Alternatives to Relieve Depression

file_download Download in HQ

Related content

description Article
Treatment-Resistant Depression (TRD) – definition, clinical manifestation, and evidence-based treatment

Treatment-resistant depression (TRD) represents a significant clinical challenge, affecting approximately 30% of individuals with major depressive disorder (MDD) who fail to respond to at least two adequate antidepressant trials.

25.09.2025 Depression
image Image Diagram titled 'Sequential Treatment Optimization Scheme for MDD' showing patient improvement over treatment time across four stages. Stage 1 includes monotherapy, dose optimization, and rTMS; Stage 2 includes augmentation, combination antidepressant, add-on treatment, rTMS/ECT; Stage 3 includes add-on psychopharmacotherapy, switch to tranylcypromine, rTMS/TBS/ECT/VNS; Stage 4 includes repetition or experimental psychopharmacotherapy/brain stimulation. Curved lines represent different patient trajectories, with horizontal dotted lines indicating thresholds for response and remission. Some lines show improvement, while others show little or worsening response over time.
Sequental Treatment Optimization Scheme for Major Depressive Disorder

Sequential treatment optimization scheme for major depressive disorder generated according to international evidence.

18.09.2025 Depression
image Image Infographic titled 'Identification and Effective Management of Factors Potentially Confounding Treatment Response'. It shows eight stacked boxes listing key steps: Check dose and duration of the current antidepressant trial Explore and reduce side effects Consider and treat comorbidities Consider and reduce ongoing stressors Evaluate treatment adherence Pharmacogenomic testing (CYP450) Check and avoid unfavorable medical interaction Evaluate initial therapies and follow recommended treatment algorithm. At the bottom, references are cited (Dold & Kasper, 2017; Kraus et al., 2019), and the image is credited to Neurotorium."
Identification and Effective Management of Factors Potentially Confounding Treatment Response

Key steps for managing factors that may confound antidepressant treatment response, including dose, side effects, comorbidities, stressors, adherence, pharmacogenomics, interactions, and treatment algorithms.

18.09.2025 Depression